Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Repligen Corp (NASDAQ:RGEN)

32.25
Delayed Data
As of 3:59pm ET
 +1.20 / +3.86%
Today’s Change
20.07
Today|||52-Week Range
34.06
+14.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.1B

Company Description

Repligen Corp. engages on the development, production and commercialization of products used in the process of manufacturing biological drugs. It also manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. The firm has developed and markets a series of OPUS line of pre-packed ""plug-and-play"" chromatography columns used for biologics purification and sells test kits to ensure final product quality. The company was founded by Alexander Rich in May 1981 and is headquartered in Waltham, MA.

Contact Information

Repligen Corp.
41 Seyon Street
Waltham Massachusetts 02453
P:(781) 250-0111
Investor Relations:
(781) 419-1881

Employees

Shareholders

Mutual fund holders59.44%
Other institutional35.65%
Individual stakeholders14.99%

Top Executives

Tony J. HuntPresident, Chief Executive Officer & Director
Steve CurranVice President-Global Operations
Jon K. SnodgresChief Financial Officer
Ralf KuriyelSenior Vice President-Research & Development
Howard BenjaminVice President-Business Development